Quick Answer
Durolane denials are common, particularly from commercial insurers that prefer lower-cost or multi-injection HA products. Durolane has two key advantages that strengthen appeals: it is both a single-injection product and non-avian-sourced (biofermentation). For patients who require non-avian HA and need the convenience of a single injection, Durolane (along with Monovisc) is one of the few options that meets both criteria — a powerful medical necessity argument.
Why Durolane Injections Get Denied
Durolane (stabilized hyaluronic acid, also called NASHA — Non-Animal Stabilized Hyaluronic Acid) is manufactured by Bioventus. It uses a unique stabilization process that creates a gel with a longer residence time in the joint.
1. Medical Necessity Not Established
The insurer determined that the submitted records do not adequately support the need for viscosupplementation. This means your OA diagnosis, severity, functional limitations, or conservative treatment history were not documented in enough detail.
2. Conservative Treatment Failure Not Documented
Insurers require at least 3 months of documented conservative therapy before approving HA injections. This includes physical therapy with specific session dates, oral medications with dosages and duration, activity modification, and in many cases a cortisone injection that provided only temporary or insufficient relief.
3. Product Not on Plan Formulary
Durolane is newer to the U.S. market compared to products like Synvisc-One and Hyalgan. Some insurers have not yet added it to their formulary or prefer established alternatives. This type of denial requires either a formulary exception appeal or a discussion with your provider about alternatives.
4. Insurer Prefers Multi-Injection Alternative
Some plans categorically prefer multi-injection HA products because individual claim amounts are lower, even though total series costs may be similar. The appeal strategy here is similar to Monovisc — emphasize compliance and access benefits.
5. Prior Authorization Not Obtained
Commercial and Medicare Advantage plans almost universally require PA for Durolane. Newer products are particularly likely to require PA even when older HA products might not.
Durolane’s Dual Advantage
Durolane is one of two FDA-approved HA products that are both single-injection AND non-avian-sourced (Monovisc is the other). If you have an avian allergy and need single-injection convenience (mobility issues, transportation barriers), Durolane is among the very few viable options. This is a strong medical necessity argument that can override formulary preferences.
Step-by-Step Appeal Process
Step 1: Review Your Denial Letter
Determine whether the denial is a general medical necessity issue, a product-specific formulary issue, or a process issue (missing PA). Each requires a different appeal approach. Note the appeal deadline.
Step 2: Gather Supporting Documentation
- Imaging: Recent knee X-rays showing osteoarthritis findings
- Conservative treatment records: Dated records of PT, medication trials, cortisone history, and activity modifications
- Functional assessment: Documented limitations in mobility, daily activities, and quality of life
- Allergy documentation (if applicable): Documented avian allergy making rooster-comb-derived HA products contraindicated. This is your strongest argument for Durolane specifically.
- Single-injection justification: Mobility or transportation limitations, history of incomplete multi-injection series, or other reasons why single-dose treatment is necessary
- Prior Durolane success: If retreating, include dates and outcomes of previous treatment
Step 3: Write Your Appeal Letter
Build your appeal around Durolane’s unique characteristics. If you have an avian allergy AND need a single injection, emphasize that Durolane is the only product that meets both criteria. See the template below.
Step 4: Submit and Follow Up
Submit via the plan’s preferred method. Confirm receipt. Request peer-to-peer review, which is especially important for formulary exception appeals where your physician can explain why Durolane specifically is needed.
Step 5: External Review Options
If internal appeal fails:
- Commercial plans: Independent external review through state insurance department
- Medicare Advantage: IRE review, then ALJ
- Original Medicare: Redetermination, then QIC reconsideration
Sample Appeal Letter Template
[Your Name] [Your Address] [City, State, ZIP] [Date]
[Insurance Company Name] [Appeals Department Address] [City, State, ZIP]
RE: Appeal of Denial — Durolane (stabilized hyaluronic acid / NASHA) Injection Member ID: [Your Member ID] Claim Number: [Claim Number from Denial Letter] Date of Service: [Date of Injection] Patient: [Your Name, DOB]
Dear Appeals Committee:
I am writing to appeal the denial of coverage for Durolane injection for my [left/right] knee osteoarthritis, denied on [denial date] for the stated reason: “[exact denial reason].”
Diagnosis: Osteoarthritis of the [left/right] knee (ICD-10: [M17.11 or M17.12]), confirmed by X-rays on [date] showing [specific findings].
Why Durolane Specifically: [If avian allergy:] I have a documented allergy to avian products (poultry/feathers/eggs), which contraindicates the use of avian-sourced HA products (Synvisc-One, Gel-One, Visco-3, Supartz, Hyalgan). Non-avian HA options include Euflexxa (3 injections), Monovisc (single injection, bacterial fermentation), Orthovisc (3-4 injections, bacterial fermentation), and Durolane (single injection, NASHA bacterial fermentation). [If mobility/access issue:] I have significant mobility and transportation limitations that make multiple weekly office visits impractical. I require a single-injection product. [If both:] Given my avian allergy AND transportation barriers, Durolane is the only FDA-approved HA product that can safely and feasibly treat my condition. [If prior success:] I previously received Durolane on [date] with [X months] of meaningful pain relief.
Conservative Treatment History:
- Physical therapy: [number] sessions from [start date] to [end date]. Result: [limited improvement].
- NSAIDs: [medication] [dosage] from [start date] to [end date]. Result: [inadequate relief].
- Cortisone injection: [date]. Provided [X weeks] of temporary relief.
- Activity modification: [describe changes].
Functional Impact: My knee pain prevents me from [specific daily activities].
I request reversal of this denial. Supporting documentation is enclosed.
Sincerely, [Your Signature] [Your Printed Name] [Phone Number]
Enclosures: Denial letter, medical records, imaging, physician letter, allergy documentation (if applicable), conservative treatment records
CPT and HCPCS Codes for Durolane
| Code Type | Code | Description |
|---|---|---|
| HCPCS (Product) | J7318 | Hyaluronan or derivative, Durolane, for intra-articular injection, per dose |
| CPT (Injection) | 20610 | Arthrocentesis, aspiration and/or injection of major joint (without ultrasound) |
| CPT (Injection w/ imaging) | 20611 | Arthrocentesis with ultrasound guidance |
| ICD-10 (Diagnosis) | M17.0 | Bilateral primary osteoarthritis of knee |
| ICD-10 (Diagnosis) | M17.11 | Primary osteoarthritis, right knee |
| ICD-10 (Diagnosis) | M17.12 | Primary osteoarthritis, left knee |
| Office Visit | 99213/99214 | Established patient office visit (if billed same day) |
Coding Note for Durolane
Durolane uses J7318, its product-specific HCPCS code. A single injection of 3 mL (60 mg NASHA) is billed as one unit. Since Durolane is a newer product, some billing systems may not have J7318 programmed — verify with your provider’s billing office that the correct code is in their system before treatment.
Durolane-Specific Coverage Facts
About Durolane
- Manufacturer: Bioventus
- Active ingredient: NASHA (Non-Animal Stabilized Hyaluronic Acid)
- Molecular weight: High (stabilized through cross-linking)
- Injection schedule: Single injection (3 mL)
- FDA approved: Yes, for knee osteoarthritis
- Source: Bacterial fermentation (non-avian)
- Key distinction: One of two single-injection, non-avian HA products available (along with Monovisc)
Medicare Coverage
Original Medicare Part B covers Durolane for knee OA under the same framework as other FDA-approved HA products. Patient pays 20% coinsurance after the $257 deductible (2026). PA is generally not required under Original Medicare. Medicare Advantage plans may require PA.
Commercial Insurance Coverage
Coverage is more variable than for established products:
- Some plans have not yet added Durolane to formulary
- Prior authorization is almost always required
- Product-preference denials are common
- Strongest appeal arguments combine avian allergy documentation with single-injection necessity
- Some plans cover Durolane without issue — always verify with your specific plan first
Common LCD Requirements
- Radiographic evidence of knee osteoarthritis
- Failure of conservative therapy for 3+ months
- 6-month minimum interval between treatments
- Coverage applies to knee joint
- Single-injection products covered equally with multi-injection products under most LCDs
Tips to Prevent Future Denials
- Verify Durolane is on your plan’s formulary before scheduling treatment. If not, get the formulary exception process started early.
- Document avian allergy if you have one — this significantly strengthens your case for Durolane
- Get prior authorization specifically for Durolane using J7318
- Confirm J7318 is programmed in your provider’s billing system before treatment
- Document single-injection necessity if applicable (mobility, transportation, compliance concerns)
- Complete conservative treatment documentation before requesting treatment
- Use correct ICD-10 codes: M17.11 (right knee), M17.12 (left knee), M17.0 (bilateral)
Frequently Asked Questions
How long does a Durolane appeal take?
Internal appeals: approximately 30 days. Expedited: 72 hours. External review: additional 30-60 days. Total: 4-12 weeks.
What is the success rate for Durolane appeals?
Appeals citing avian allergy as the reason for needing Durolane have a strong success rate because the medical necessity is clear. Product-preference denials without an allergy argument are harder. Medical necessity denials with complete documentation have a 40-60% overturn rate.
Can my doctor help with the appeal?
Your doctor’s letter is critical, especially for formulary exception requests. Emphasize the specific clinical reasons for choosing Durolane over alternatives. Peer-to-peer review is highly recommended.
What if my second appeal is denied?
Request external review. If you have a documented avian allergy and need a single injection, external reviewers are likely to view your case favorably. If there is no allergy or single-injection need, consider Euflexxa (non-avian, 3 injections) or a multi-injection avian product as alternatives.
I have an avian allergy. Is Durolane my only option?
Not your only option, but possibly your best one. Euflexxa is also non-avian-sourced but requires 3 weekly injections. If you need non-avian AND single-injection, Durolane and Monovisc are both FDA-approved options. Document both requirements clearly in your appeal.